Rabiya S Tuma. Show Affiliations »
Abstract
Entities: Disease
Mesh： See more » Adenocarcinoma, Clear Cell/drug therapyAdenocarcinoma, Clear Cell/metabolismAngiogenesis Inhibitors/therapeutic useAntineoplastic Agents/therapeutic useClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicDisease-Free SurvivalEnzyme Inhibitors/therapeutic useHumansIndoles/therapeutic useKidney Neoplasms/drug therapyKidney Neoplasms/metabolismPhosphotransferases/antagonists & inhibitorsPyrroles/therapeutic useReceptors, Platelet-Derived Growth Factor/drug effectsReceptors, Vascular Endothelial Growth Factor/drug effectsSunitinibTreatment Outcome
Substances： See more » Angiogenesis InhibitorsAntineoplastic AgentsEnzyme InhibitorsIndolesPyrrolesPhosphotransferasesReceptors, Platelet-Derived Growth FactorReceptors, Vascular Endothelial Growth FactorSunitinib
Year: 2004 PMID： 15339961 DOI： 10.1093/jnci/96.17.1270
Source DB: PubMed Journal: J Natl Cancer Inst ISSN： 0027-8874 Impact factor: 13.506